We are live on ! Find out more

Myriad Genetics

MYGN

Market cap $363M

3.79 USD

+0.37

10.82%

At close Updated Sep 14, 4:00 PM EDT

Pre-market

After hours

3.77

-0.02

0.53%

1 day

10.82%

5 days

19.18%

1 month

25.08%

3 months

-12.27%

6 months

-17.43%

Year to date

-38.27%

1 year

-48.15%

5 years

-88.09%

10 years

-82.69%

About: Myriad Genetics Inc is a molecular diagnostics and precision medicine company committed to advancing health and well-being for all. The company develops and commercializes molecular tests that help patients and providers uncover genetic insights. Its tests assess the risk of developing disease or disease progression and guide treatment decisions across medical specialties, supporting earlier detection, more precise treatment, and lowering healthcare costs. Its tests include BRACAnalysis CDx, EndoPredict, FirstGene, Foresight, GeneSight, MyChoice CDx, MyRisk (cancer treatment), MyRisk (cancer risk), Prequel, Precise Tumor, Prolaris, and SneakPeek. The company operates in the US and Rest of World, with maximum revenue from the US.

Employees: 2,700

Healthcare Diagnostics & Research

News

Positive

Neutral

Negative

Sentiment 3-Months

Positive 14.3%

Neutral 76.2%

Negative 9.5%

This Biotech Stock Got a Rare Double-Downgrade. Its Profitability Problem Just Got Worse.

Piper Sandler cuts Myriad Genetics stock to Underweight, citing doubts about the genetic testing company's path to sustainable profitability.

This Biotech Stock Got a Rare Double-Downgrade. Its Profitability Problem Just Got Worse.

Myriad Genetics to Present at 2026 Wells Fargo Healthcare Conference

SALT LAKE CITY, Aug. 27, 2026 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in molecular diagnostic testing and precision medicine, today announces Myriad management will present at the 21st Annual Wells Fargo Healthcare Conference in Boston on Thursday, September 10, 2026 at 11:00am EST. The presentation will be available through a live audio webcast link in the investor information section of Myriad's website at investor.myriad.com.

Myriad Genetics to Present at 2026 Wells Fargo Healthcare Conference

MYGN SHAREHOLDER ALERT: Myriad Genetics Inc. Investors Encouraged to Contact Kirby McInerney LLP About Potential Securities Laws Violations

NEW YORK--(BUSINESS WIRE)---- $MYGN #classactionlawsuit--The law firm of Kirby McInerney LLP reminds investors of its investigation on behalf of Myriad Genetics, Inc. (“Myriad Genetics” or the “Company”) (NASDAQ: MYGN) investors concerning the Company's and/or members of its senior management's possible violation of the federal securities laws or other unlawful business practices. [LEARN MORE ABOUT THE INVESTIGATION] What Happened? On July 30, 2026, Myriad Genetics reported that its second-quarter revenue declined 11% year-.

MYGN SHAREHOLDER ALERT: Myriad Genetics Inc. Investors Encouraged to Contact Kirby McInerney LLP About Potential Securities Laws Violations

Myriad Genetics (MYGN) Securities Investigation Notice - Levi & Korsinsky

Myriad Genetics reported Q2 2026 revenue of approximately $190.7 million against consensus of roughly $206-208 million, then cut full-year revenue guidance by about $90 million at the midpoint and suspended adjusted EBITDA guidance. Levi & Korsinsky is investigating potential securities law violations on behalf of MYGN investors.

Myriad Genetics (MYGN) Securities Investigation Notice - Levi & Korsinsky

MYGN Investors Have Opportunity to Join Myriad Genetics, Inc. Fraud Investigation with SBS Law

LOS ANGELES--(BUSINESS WIRE)---- $MYGN--MYGN Investors Have Opportunity to Join Myriad Genetics, Inc. Fraud Investigation with SBS Law.

MYGN Investors Have Opportunity to Join Myriad Genetics, Inc. Fraud Investigation with SBS Law

MYRIAD INVESTIGATION ALERT: Bragar Eagel & Squire, P.C. is Investigating Myriad Genetics, Inc. on Behalf of Myriad Stockholders and Encourages Investors to Contact the Firm

Bragar Eagel & Squire, P.C. Litigation Partner Brandon Walker Encourages Investors Who Suffered Losses In Myriad (MYGN) To Contact Him Directly To Discuss Their Options

MYRIAD INVESTIGATION ALERT: Bragar Eagel & Squire, P.C. is Investigating Myriad Genetics, Inc. on Behalf of Myriad Stockholders and Encourages Investors to Contact the Firm

Levi & Korsinsky Notifies Investors of Pending Investigation Into Securities Claims Involving Myriad Genetics (MYGN)

Myriad Genetics missed Q2 2026 revenue consensus by roughly 7%-8% -- $190.7 million against Wall Street's $206-$208 million -- and MYGN shareholders took the hit. Levi & Korsinsky is investigating potential securities law violations on behalf of MYGN investors who suffered losses. Myriad Genetics missed Q2 2026 revenue consensus by roughly 7%-8% -- $190.7 million against Wall Street's $206-$208 million -- and MYGN shareholders took the hit. Levi & Korsinsky is investigating potential securities law violations on behalf of MYGN investors who suffered losses.

Levi & Korsinsky Notifies Investors of Pending Investigation Into Securities Claims Involving Myriad Genetics (MYGN)

MYRIAD GENETICS, INC. INVESTOR ALERT: Kirby McInerney LLP Announces Investigation Into Potential Securities Fraud

NEW YORK, Aug. 05, 2026 (GLOBE NEWSWIRE) -- The law firm of Kirby McInerney LLP is investigating potential claims against Myriad Genetics, Inc. (“Myriad Genetics” or the “Company”) (NASDAQ: MYGN). The investigation concerns whether the Company and/or members of its senior management may have violated federal securities laws or engaged in other unlawful business practices.

MYRIAD GENETICS, INC. INVESTOR ALERT: Kirby McInerney LLP Announces Investigation Into Potential Securities Fraud

MYGN Investor Alert: Levi & Korsinsky Notifies Investors of Investigation Into Myriad Genetics (MYGN)

NEW YORK--(BUSINESS WIRE)--On May 5, 2026, Myriad Genetics (NASDAQ: MYGN) reaffirmed adjusted EBITDA of $37 million to $49 million and adjusted gross margin of 68% to 69% for full-year 2026. Roughly three months later, the adjusted EBITDA range was suspended outright and MYGN shares dropped. If you held Myriad Genetics stock and lost money, you are encouraged to submit your loss information now. You may also contact Joseph E. Levi, Esq. via email at [email protected] or by telephone at (2.

MYGN Investor Alert: Levi & Korsinsky Notifies Investors of Investigation Into Myriad Genetics (MYGN)

Myriad Genetics, Inc. (MYGN) Investors Who Suffered Losses Are Encouraged to Contact Johnson Fistel

SAN DIEGO, Aug. 04, 2026 (GLOBE NEWSWIRE) -- Johnson Fistel, PLLP is investigating whether Myriad Genetics, Inc. (“Myriad Genetics” or the “Company”) (NASDAQ: MYGN) or certain of its officers and directors violated federal securities laws by misrepresenting or failing to timely disclose material information to investors.

Myriad Genetics, Inc. (MYGN) Investors Who Suffered Losses Are Encouraged to Contact Johnson Fistel

See News Rankings

Price charts implemented using Lightweight Charts™